Literature DB >> 23002080

Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3β.

Lulu Mao1, Robert T Dauchy, David E Blask, Lauren M Slakey, Shulin Xiang, Lin Yuan, Erin M Dauchy, Bin Shan, George C Brainard, John P Hanifin, Tripp Frasch, Tamika T Duplessis, Steven M Hill.   

Abstract

Disturbed sleep-wake cycle and circadian rhythmicity are associated with cancer, but the underlying mechanisms are unknown. Employing a tissue-isolated human breast xenograft tumor nude rat model, we observed that glycogen synthase kinase 3β (GSK3β), an enzyme critical in metabolism and cell proliferation/survival, exhibits a circadian rhythm of phosphorylation in human breast tumors. Exposure to light-at-night suppresses the nocturnal pineal melatonin synthesis, disrupting the circadian rhythm of GSK3β phosphorylation. Melatonin activates GSK3β by inhibiting the serine-threonine kinase Akt phosphorylation, inducing β-catenin degradation and inhibiting epithelial-to-mesenchymal transition, a fundamental process underlying cancer metastasis. Thus, chronic circadian disruption by light-at-night via occupational exposure or age-related sleep disturbances may contribute to cancer incidence and the metastatic spread of breast cancer by inhibiting GSK3β activity and driving epithelial-to-mesenchymal transition in breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23002080      PMCID: PMC3487627          DOI: 10.1210/me.2012-1071

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  43 in total

Review 1.  The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it.

Authors:  Elizabeth D Hay
Journal:  Dev Dyn       Date:  2005-07       Impact factor: 3.780

2.  Estimates of the worldwide frequency of sixteen major cancers in 1980.

Authors:  D M Parkin; E Läärä; C S Muir
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

3.  Involvement of the mt1 melatonin receptor in human breast cancer.

Authors:  P T Ram; J Dai; L Yuan; C Dong; T L Kiefer; L Lai; S M Hill
Journal:  Cancer Lett       Date:  2002-05-28       Impact factor: 8.679

4.  Chemoprevention of NMU-induced rat mammary carcinoma with the combination of melatonin and 9-cis-retinoic acid.

Authors:  S R Teplitzky; T L Kiefer; Q Cheng; P D Dwivedi; K Moroz; L Myers; M B Anderson; A Collins; J Dai; L Yuan; L L Spriggs; D E Blask; S M Hill
Journal:  Cancer Lett       Date:  2001-07-26       Impact factor: 8.679

Review 5.  Breast cancer: influence of endocrine hormones, growth factors and genetic alterations.

Authors:  R B Dickson; M D Johnson; D el-Ashry; Y E Shi; M Bano; G Zugmaier; B Ziff; M E Lippman; S Chrysogelos
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

6.  KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.

Authors:  Muralidharan Anbalagan; Latonya Carrier; Seth Glodowski; David Hangauer; Bin Shan; Brian G Rowan
Journal:  Breast Cancer Res Treat       Date:  2011-04-21       Impact factor: 4.872

Review 7.  Steroid hormone receptors in breast cancer management.

Authors:  C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1998       Impact factor: 4.872

8.  SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock.

Authors:  Ray-Chang Wu; Qin Feng; David M Lonard; Bert W O'Malley
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

9.  Transactivation of vimentin by beta-catenin in human breast cancer cells.

Authors:  Christine Gilles; Myriam Polette; Mélanie Mestdagt; Béatrice Nawrocki-Raby; Philippe Ruggeri; Philippe Birembaut; Jean-Michel Foidart
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

10.  MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells.

Authors:  Lin Yuan; April R Collins; Jun Dai; Margarita L Dubocovich; Steven M Hill
Journal:  Mol Cell Endocrinol       Date:  2002-06-28       Impact factor: 4.102

View more
  33 in total

Review 1.  Melatonin: an inhibitor of breast cancer.

Authors:  Steven M Hill; Victoria P Belancio; Robert T Dauchy; Shulin Xiang; Samantha Brimer; Lulu Mao; Adam Hauch; Peter W Lundberg; Whitney Summers; Lin Yuan; Tripp Frasch; David E Blask
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

2.  Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.

Authors:  Robert T Dauchy; Shulin Xiang; Lulu Mao; Samantha Brimer; Melissa A Wren; Lin Yuan; Muralidharan Anbalagan; Adam Hauch; Tripp Frasch; Brian G Rowan; David E Blask; Steven M Hill
Journal:  Cancer Res       Date:  2014-08-01       Impact factor: 12.701

Review 3.  Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease.

Authors:  Gianluca Tosini; Sharon Owino; Jean-Luc Guillaume; Ralf Jockers
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

Review 4.  Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Authors:  William H Goodson; Leroy Lowe; David O Carpenter; Michael Gilbertson; Abdul Manaf Ali; Adela Lopez de Cerain Salsamendi; Ahmed Lasfar; Amancio Carnero; Amaya Azqueta; Amedeo Amedei; Amelia K Charles; Andrew R Collins; Andrew Ward; Anna C Salzberg; Annamaria Colacci; Ann-Karin Olsen; Arthur Berg; Barry J Barclay; Binhua P Zhou; Carmen Blanco-Aparicio; Carolyn J Baglole; Chenfang Dong; Chiara Mondello; Chia-Wen Hsu; Christian C Naus; Clement Yedjou; Colleen S Curran; Dale W Laird; Daniel C Koch; Danielle J Carlin; Dean W Felsher; Debasish Roy; Dustin G Brown; Edward Ratovitski; Elizabeth P Ryan; Emanuela Corsini; Emilio Rojas; Eun-Yi Moon; Ezio Laconi; Fabio Marongiu; Fahd Al-Mulla; Ferdinando Chiaradonna; Firouz Darroudi; Francis L Martin; Frederik J Van Schooten; Gary S Goldberg; Gerard Wagemaker; Gladys N Nangami; Gloria M Calaf; Graeme Williams; Gregory T Wolf; Gudrun Koppen; Gunnar Brunborg; H Kim Lyerly; Harini Krishnan; Hasiah Ab Hamid; Hemad Yasaei; Hideko Sone; Hiroshi Kondoh; Hosni K Salem; Hsue-Yin Hsu; Hyun Ho Park; Igor Koturbash; Isabelle R Miousse; A Ivana Scovassi; James E Klaunig; Jan Vondráček; Jayadev Raju; Jesse Roman; John Pierce Wise; Jonathan R Whitfield; Jordan Woodrick; Joseph A Christopher; Josiah Ochieng; Juan Fernando Martinez-Leal; Judith Weisz; Julia Kravchenko; Jun Sun; Kalan R Prudhomme; Kannan Badri Narayanan; Karine A Cohen-Solal; Kim Moorwood; Laetitia Gonzalez; Laura Soucek; Le Jian; Leandro S D'Abronzo; Liang-Tzung Lin; Lin Li; Linda Gulliver; Lisa J McCawley; Lorenzo Memeo; Louis Vermeulen; Luc Leyns; Luoping Zhang; Mahara Valverde; Mahin Khatami; Maria Fiammetta Romano; Marion Chapellier; Marc A Williams; Mark Wade; Masoud H Manjili; Matilde E Lleonart; Menghang Xia; Michael J Gonzalez; Michalis V Karamouzis; Micheline Kirsch-Volders; Monica Vaccari; Nancy B Kuemmerle; Neetu Singh; Nichola Cruickshanks; Nicole Kleinstreuer; Nik van Larebeke; Nuzhat Ahmed; Olugbemiga Ogunkua; P K Krishnakumar; Pankaj Vadgama; Paola A Marignani; Paramita M Ghosh; Patricia Ostrosky-Wegman; Patricia A Thompson; Paul Dent; Petr Heneberg; Philippa Darbre; Po Sing Leung; Pratima Nangia-Makker; Qiang Shawn Cheng; R Brooks Robey; Rabeah Al-Temaimi; Rabindra Roy; Rafaela Andrade-Vieira; Ranjeet K Sinha; Rekha Mehta; Renza Vento; Riccardo Di Fiore; Richard Ponce-Cusi; Rita Dornetshuber-Fleiss; Rita Nahta; Robert C Castellino; Roberta Palorini; Roslida Abd Hamid; Sabine A S Langie; Sakina E Eltom; Samira A Brooks; Sandra Ryeom; Sandra S Wise; Sarah N Bay; Shelley A Harris; Silvana Papagerakis; Simona Romano; Sofia Pavanello; Staffan Eriksson; Stefano Forte; Stephanie C Casey; Sudjit Luanpitpong; Tae-Jin Lee; Takemi Otsuki; Tao Chen; Thierry Massfelder; Thomas Sanderson; Tiziana Guarnieri; Tove Hultman; Valérian Dormoy; Valerie Odero-Marah; Venkata Sabbisetti; Veronique Maguer-Satta; W Kimryn Rathmell; Wilhelm Engström; William K Decker; William H Bisson; Yon Rojanasakul; Yunus Luqmani; Zhenbang Chen; Zhiwei Hu
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

5.  Melatonin Represses Metastasis in Her2-Postive Human Breast Cancer Cells by Suppressing RSK2 Expression.

Authors:  Lulu Mao; Whitney Summers; Shulin Xiang; Lin Yuan; Robert T Dauchy; Amberly Reynolds; Melissa A Wren-Dail; David Pointer; Tripp Frasch; David E Blask; Steven M Hill
Journal:  Mol Cancer Res       Date:  2016-08-17       Impact factor: 5.852

Review 6.  The emerging link between cancer, metabolism, and circadian rhythms.

Authors:  Selma Masri; Paolo Sassone-Corsi
Journal:  Nat Med       Date:  2018-12-06       Impact factor: 53.440

Review 7.  Melatonin and its mechanism of action in the female reproductive system and related malignancies.

Authors:  Maryam Ezzati; Kobra Velaei; Raziyeh Kheirjou
Journal:  Mol Cell Biochem       Date:  2021-04-17       Impact factor: 3.396

8.  CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells.

Authors:  Wootae Kim; Joo-Won Jeong; Ja-Eun Kim
Journal:  Tumour Biol       Date:  2014-08-02

9.  Insulin and IGF1 enhance IL-17-induced chemokine expression through a GSK3B-dependent mechanism: a new target for melatonin's anti-inflammatory action.

Authors:  Dongxia Ge; Robert T Dauchy; Sen Liu; Qiuyang Zhang; Lulu Mao; Erin M Dauchy; David E Blask; Steven M Hill; Brian G Rowan; George C Brainard; John P Hanifin; Kate S Cecil; Zhenggang Xiong; Leann Myers; Zongbing You
Journal:  J Pineal Res       Date:  2013-08-20       Impact factor: 13.007

10.  Daytime Blue Light Enhances the Nighttime Circadian Melatonin Inhibition of Human Prostate Cancer Growth.

Authors:  Robert T Dauchy; Aaron E Hoffman; Melissa A Wren-Dail; John P Hanifin; Benjamin Warfield; George C Brainard; Shulin Xiang; Lin Yuan; Steven M Hill; Victoria P Belancio; Erin M Dauchy; Kara Smith; David E Blask
Journal:  Comp Med       Date:  2015-12       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.